Risk of fatal pulmonary embolism in patients with treated venous thromboembolism

JAMA

Volumn 279, Issue 6, 1998, Pages 458-462

  Douketis, James D ^a,b   Kearon, Clive ^a   Bates, Shannon ^a   Duku, Eric K ^a   Ginsberg, Jeffrey S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; DEEP VEIN THROMBOSIS; FATALITY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 0032507023     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.6.458     Document Type: Review

References (43)

1. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman RW, Hirsh J, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott & Co; 1994:1275-1296.
2. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med. 1996;125:1-7.
3. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med. 1991;151:933-938.
4. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:259-270.
5. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA. 1976;236:1477-1480.
6. Lensing AWA, Buller HR, Prandoni P, et al. Contrast venography, the gold standard for the diagnosis of DVT: improvement in observer agreement. Thromb Haemost. 1992;67:8-12.
7. White RH, McGahan JP, Daschbach MM, Harting RP. Diagnosis of deep-vein thrombosis using duplex ultrasound. Ann Intern Med. 1989;111:297-304.
8. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990; 263:2753-2759.
9. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute recurrent deep vein thrombosis: a diagnostic challenge. Circulation. 1983;67:901-906.
10. Prandoni P, Cogo A, Bernardi E, et al. A simple ultrasound approach for detection of recurrent proximal vein thrombosis. Circulation. 1993;88: 1730-1735.
11. Huisman MV, Buller HR, ten Cate JW. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Arch Intern Med. 1988;148:681-683.
12. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: Wiley; 1973;1:43-47.
13. Hull R, Delorme T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-85.
14. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. Acta Med Scand. 1985;217:547-552.
15. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep vein thrombosis (DVT). Thromb Haemost. 1990;64:506-510.
16. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicentre trial. Thromb Haemost. 1992;68:14-18.
17. Hull R, Delorme T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982;306:189-194.
18. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307: 1676-1681.
19. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;72:186-190.
20. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
21. A Collaborative European Multicentre Study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1991;65: 251-256.
22. Brandjes DPM, Heijboer H, Buller HR, Rijk MD, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-1489.
23. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445.
24. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
25. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993;153:1541-1546.
26. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
27. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
28. Lagerstedt CI, Olsson C-G, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985;2:515-518.
29. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
30. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315: 1109-1114.
31. Huisman MV, Buller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. N Engl J Med. 1986;314:823-828.
32. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. Ann Intern Med. 1985;102:21-28.
33. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for venous thromboembolism. N Engl J Med. 1997;337: 657-662.
34. Simmoneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
35. Hull RD, Raskob GE, Ginsberg JS, et al. A non-invasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994;154:289-297.
36. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983;98:891-899.
37. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992; 326:1240-1245.
38. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med. 1992;116:279-284.
39. Dolovich LR, Ginsberg JS. Low molecular weight heparin in the treatment of venous thromboembolism: an updated meta-analysis. Vessels. 1997;3:4-11.
40. Gallus A, Tillet J, Jackman J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2:1293-1296.
41. Ridker PM, Mitelich JP, Stampfer MJ, Goldhaber SZ, Lindpainter K, Hennekens CH. Factor V Leiden and risk of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
42. Schulman S, Rhedin A-N, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-1665.
43. Kearon C, for the LAFIT Investigators. Two years of warfarin versus placebo following three months of anticoagulation for a first episode of idiopathic venous thromboembolism (VTE). Thromb Haemost. 1997;78:767. Abstract HI-3.